<span item_type="fundamental" item_id="062c1b1e9327a0743cbe60dc1432ff6b" counter_id="ST/US/UTMD" env="prod"></span><span item_type="announcement" item_id="574794368450366977" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 9.812 M.</p><p>EPS: As of FY2025 Q3, the actual value is USD 0.82.</p><p>EBIT: As of FY2025 Q3, the actual value is USD 2.611 M.</p><p></p><h3>Segment Revenue</h3><ul><li>Total worldwide consolidated sales for Utah Medical Products, Inc. in 3Q 2025 were $9,812, a decrease of 1.9% compared to $10,005 in 3Q 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/706698/000109690625001708/utmd_ex99z1.htm"></span></li><li>For the first nine months of 2025, total consolidated sales were $29,475, a decrease of 7.2% compared to $31,745 in 9M 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/706698/000109690625001708/utmd_ex99z1.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li>Gross Profit for 3Q 2025 was $5,604, a decrease of 3.4% compared to $5,802 in 3Q 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/706698/000109690625001708/utmd_ex99z1.htm"></span></li><li>Operating Income for 3Q 2025 was $2,611, a decrease of 21.9% compared to $3,343 in 3Q 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/706698/000109690625001708/utmd_ex99z1.htm"></span></li><li>Net Income for 3Q 2025 was $2,631, a decrease of 26.2% compared to $3,564 in 3Q 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/706698/000109690625001708/utmd_ex99z1.htm"></span></li><li>Gross Profit Margin for 3Q 2025 was 57.1%, compared to 58.0% in 3Q 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/706698/000109690625001708/utmd_ex99z1.htm"></span></li><li>Operating Income Margin for 3Q 2025 was 26.6%, compared to 33.4% in 3Q 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/706698/000109690625001708/utmd_ex99z1.htm"></span></li></ul><h3>Cash Flow</h3><ul><li>Cash and investments increased to $84,267 at the end of September 30, 2025, from $82,976 at the end of 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/706698/000109690625001708/utmd_ex99z1.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li>Adjusted consolidated EBITDA for 3Q 2025 was $4,170, a decrease of 15.9% compared to $4,958 in 3Q 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/706698/000109690625001708/utmd_ex99z1.htm"></span></li><li>Adjusted consolidated EBITDA for 9M 2025 was $13,493, a decrease of 12.7% compared to $15,447 in 9M 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/706698/000109690625001708/utmd_ex99z1.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>Management expects total annual 2025 consolidated sales to be about 7% lower compared to 2024, instead of the initial projection of a 5% decrease.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/706698/000109690625001708/utmd_ex99z1.htm"></span></li><li>Adjusted consolidated EBITDA for the 2025 calendar year is expected to be in the range of $17 to $18 million.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/706698/000109690625001708/utmd_ex99z1.htm"></span></li><li>Investors are cautioned that actual events may differ from projections due to various risk factors including global economic conditions and regulatory interventions.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/706698/000109690625001708/utmd_ex99z1.htm"></span></li></ul>

Utah Medical Products | 8-K: FY2025 Q3 Revenue: USD 9.812 M